News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Shocking news today! SAFC was suspened now due to its "SEC Reporting Delinquent" status as I warned before! Folks, the only way to recover the losses from here is: buy a Investment-Garde OTC stock which has Huge Positive Book Value at 20 Times of its trading price...
|
Followers
|
82
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
12651
|
|
Created
|
11/07/12
|
Type
|
Free
|
| Moderators | |||
(3) Marketable Securities
On November 26, 2012, the Company entered into a share exchange agreement with Biomedix Incubator, an Israeli company and a shareholder of Gefen Biomed Investments, a publicly traded Israeli company. The Company issued 1,082,851 shares to Biomedix Incubator and received in return 921,790* shares of Gefen Biomed Investments. The shares were valued at $194,913 which was the market price of the Company’s shares on the date of the exchange. The investment in Gefen is less than 4.9% of Gefen’s outstanding stock.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9453715
327
* Gefen BioMed Investments currently trades @ 15.20 ILS or $3.87 USD per share which makes the total value of this investment $3,567,327 USD
http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=GEFEN:IT
JERUSALEM, November 1, 2012 /PRNewswire/ --
SafeCode Drug Technologies Corp. (OTCBB: SAFC), a developer of patent-pending voice recognition technology that reduces the risks of errors during the administration of prescription medications, announced today that shares of SafeCode Drug Technologies common stock have commenced trading on the OTC Bulletin Board under the symbol "SAFC".
Trading began shortly after the company was granted eligibility status by the Depository Trust Company (DTC).
SafeCode is the developer of the world's first patent-pending voice recognition technology used to confirm prescription medications prior to their administration at home or in a medical center.
Using SafeCode technology, prescription medications stored in specially designed locked containers can only be accessed and administered once the caregiver or patient correctly announces the name of the drug.
The technology ensures that the appropriate medication is being administered, as mistakes have accounted for thousands of deaths in recent years. Often, nurses, doctors or patients are not careful when giving or taking medications, and many medication's packaging may look similar. SafeCode Technology prevents medication errors, and thereby reduces the risk of severe injury or accidental death.
"We are certain that the wider investment community will recognize the commercial potential for SafeCode Drug Technologies," said Joel Klopfer , Chief Executive Officer of SafeCode Drug Technologies. "We are excited to bring this potentially life-saving technology to market, and will keep our investors abreast of the company's development in the coming weeks and months."
About SafeCode Drug Technologies
SafeCode Drug Technologies is the developer of a patent-pending voice recognition technology that provides an essential degree of security that can effectively prevent unauthorized administration of a prescription medication.
Forward-Looking Statements
This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of SafeCode Drug Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. SafeCode Drug Technologies Corp. public filings may be viewed at http://www.sec.gov.
Contact:JERUSALEM, October 16, 2012 /PRNewswire/ --
SafeCode Drug Technologies Corp. (OTCBB: SAFC), a developer of a patent-pending voice recognition technology that reduces the risks of errors during of administration of prescription medications, announced today that the company has been granted eligibility status by the Depository Trust Company (DTC). The DTC provides banks, brokerage firms and other institutions with an efficient means of moving securities and settling trades electronically.
"SafeCode Drug Technologies has acquired the patent-pending voice recognition technology that can significantly reduce the risks of errors of administering the wrong medication," said Joel Klopfer, CEO of SafeCode Drug Technologies. "We are excited to being able in the future to bring this potentially life-saving technology to the market."
About SafeCode Drug Technologies
SafeCode Drug Technologies is the developer of a patent-pending voice recognition technology that provides an essential degree of security that can effectively prevent unauthorized administration of a prescription medication.
Forward-Looking Statements
This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of SafeCode Drug Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. SafeCode Drug Technologies Corp. public filings may be viewed at http://www.sec.gov.
Contact:
Joel Klopfer
CEO
+97225021322
Joel.Klopfer1@gmail.com
SOURCE Safecode Drug Technologies Corp.
